H. Nunes (Bobigny, France), E. Bendstrup (Aarhus C, Denmark)
LATE-BREAKING ABSTRACT: Current management of patients with idiopathic pulmonary fibrosis in clinical practice: INSIGHTS-IPF registry
J. Behr, M. Kreuter, M. Hoeper, J. Klotsche, H. Wirtz, D. Koschel, S. Andreas, M. Claussen, C. Grohé, D. Pittrow (Munich, Gauting, Heidelberg, Berlin, Leipzig, Coswig, Immenhausen, Grosshansdorf, Dresden, Germany)
|   |
Acute exacerbation of idiopathic pulmonary fibrosis: Analysis in a post-marketing surveillance of pirfenidone
H. Taniguchi, A. Azuma, T. Ogura, Y. Inoue, K. Chida, M. Bando, S. Kakutani, S. Inagaki, M. Suga, Y. Sugiyama, S. Kudoh, T. Nukiwa (Seto, Tokyo, Yokohama, Sakai, Hamamatsu, Shimotsuke, Osaka, Kumamoto, Kiyose, Shibata, Japan)
|  |
Long-term safety of pirfenidone in RECAP, an open-label extension study in patients with idiopathic pulmonary fibrosis, interim results
U. Costabel, C. Albera, E. Fagan, W. Bradford, T. King, P. Noble, S. Sahn, D. Valeyre, R. du Bois (Essen, Germany; Orbassano (Turin), Italy; Brisbane, San Francisco, West Hollywood, Charleston, United States Of America; Bobigny, France; London, United Kingdom)
| |
Pirfenidone post-authorization safety registry (PASSPORT) – Interim analysis of IPF treatment
D. Koschel, V. Cottin, M. Skold, S. Tomassetti, A. Azuma, C. Giot, D. Yocum, S. Hamza, T. M. Maher (Coswig, Germany; Lyon, France; Stockholm, Sweden; Forli, Italy; Tokyo, Japan; Muttenz, Switzerland; Brisbane, United States Of America; London, United Kingdom)
| |
Long-term survival analysis: Pirfenidone compared to standard care for the treatment of patients with idiopathic pulmonary fibrosis
N. Roskell, O. Saunders, D. Lee, M. Fisher (Sheffield, London, United Kingdom)
| |
Reduction in disease progression with nintedanib in the INPULSIS™ trials
V. Cottin, H. Taniguchi, H. R. Collard, L. Richeldi, S. Stowasser, I. Tschoepe, R. Schlenker-Herceg, G. Raghu (Lyon, Reims, France; Aichi, Japan; San Francisco, Ridgefield, Seattle, United States Of America; Southampton, United Kingdom; Ingelheim am Rhein, Germany)
| |
Effect of baseline FVC on decline in lung function with nintedanib: Results from the INPULSIS™ trials
U. Costabel, Y. Inoue, L. Richeldi, H. R. Collard, S. Stowasser, I. Tschoepe, A. Azuma (Essen, Ingelheim am Rhein, Germany; Osaka, Tokyo, Japan; Southampton, United Kingdom; San Francisco, United States Of America; Reims, France)
| |
Sensitivity analyses from the INPULSIS™ trials of nintedanib
M. Kolb, H. R. Collard, S. Stowasser, M. Girard, R. Schlenker-Herceg, L. Richeldi (Hamilton, Canada; San Francisco, Ridgefield, United States Of America; Ingelheim am Rhein, Germany; Reims, France; Southampton, United Kingdom)
| |